Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Comprehensive Loss

v3.20.4
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 4,299,062 3,372,103
Sales and Marketing Expenses 22,963 25,000
Research and Development Expenses 7,963,678
Litigation Settlement Expenses 75,000
Loss from Operations (12,285,703) (3,472,103)
Other (Income) Expenses    
Loss on Disposal of Non-Current Assets 3,042 9,576
Foreign Currency Transaction (Gain) Loss (93) 5,051
Gain on Fair Market Value Change of Equity Investments (54,100)
(Gain) Loss on Investments 36,714 (3,952)
Interest and Dividend Income (119,052) (101,483)
Total Other Income (133,489) (90,808)
Loss Before Income Taxes (12,152,214) (3,381,295)
Income Tax Benefit
Net Loss from Continuing Operations (12,152,214) (3,381,295)
Net Loss from Discontinued Operations (5,428,395) (506,954)
Net Loss (17,580,609) (3,888,249)
Other Comprehensive Income (Loss)    
Net Unrealized Gain on Marketable Securities 43,799
Total Other Comprehensive Income 43,799
Comprehensive Loss $ (17,580,609) $ (3,844,450)
Basic and Diluted Loss per Common Share from Continuing Operations $ (1.72) $ (5.52)
Basic and Diluted Loss per Common Share from Discontinued Operations (0.77) (0.83)
Basic and Diluted Loss per Common Share $ (2.49) $ (6.35)
Weighted average basic and diluted common shares outstanding 7,052,686 612,672